<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said a new facility in Malta that will be used to produce its potentially breakthrough plant-based COVID-19 treatment has been completed on time and to budget. The plan is to immediately begin the equipment fit-out and commissioning of the operation, which will produce 20,000 liquid doses per day of CimetrA, double the output originally envisaged.
...read full article on Proactive Investors
